|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
606.85
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 3,624.27 | 3,338.30 | 3,466.67 | 3,100.64 | Total Expenditure | 3,431.05 | 3,411.37 | 3,383.58 | 3,187.96 | PBIDT (Excl OI) | 193.22 | -73.07 | 83.09 | -87.32 | Other Income | 99.42 | 75.81 | 58.26 | 37.88 | Operating Profit | 292.65 | 2.74 | 141.35 | -49.43 | Interest | 23.62 | 38.25 | 24.75 | 29.32 | Exceptional Items | 680.15 | 0 | 0 | -1,076.42 | PBDT | 949.18 | -35.51 | 116.60 | -1,155.17 | Depreciation | 256.17 | 272.59 | 273.63 | 283.18 | Profit Before Tax | 693.01 | -308.10 | -157.03 | -1,438.35 | Tax | 0 | 0 | 0 | 0 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 693.01 | -308.10 | -157.03 | -1,438.35 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 693.01 | -308.10 | -157.03 | -1,438.35 | Equity Capital | 140.81 | 140.81 | 140.81 | 140.81 | Face Value (IN RS) | 2 | 2 | 2 | 2 | Reserves | | | | | Calculated EPS | 9.84 | -4.38 | -2.23 | -20.43 | Calculated EPS (Annualised) | 39.37 | -17.50 | -8.92 | -81.72 | No of Public Share Holdings | 20,965,164.00 | 20,975,618.00 | 34,544,735.00 | 34,544,735.00 | % of Public Share Holdings | 29.78 | 29.79 | 49.07 | 49.07 | | | | | | PBIDTM% (Excl OI) | 5.33 | -2.19 | 2.40 | -2.82 | PBIDTM% | 8.07 | 0.08 | 4.08 | -1.59 | PBDTM% | 26.19 | -1.06 | 3.36 | -37.26 | PBTM% | 19.12 | -9.23 | -4.53 | -46.39 | PATM% | 19.12 | -9.23 | -4.53 | -46.39 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|